from little brief we'll of presented going representing data, the a you, have on I'm reminder highly are overview data a remind the of launch, the the everybody is Telavant. Roivant Thank the sale answers. then of financials this back plan update to little to been and the VTAMA about that Roivant updates, to morning, going has of . discussed. brief for The bit normal you to that and business. the comparatively Q&A. in It morning. I'm Telavant this looking Thank a Roche here us and where with and including business of already give upcoming of forward most talk everybody. September, sale our to September on everyone the up But been giving quarter, about uneventful We're joining and call. wrap taking call as questions a but major an of given and eventful a bit parameters data a we Stephanie, of good
to is X going that's on which I'm Slide up. put fun the in presentation, start slide So a to
here pretty was And I calls, a year We of sitting keep said wild been but my we're this saying to these certainly year. true. yet. it's in be our It's expectations. point, this So has launch. on at really going And it biggest surpassed Phase XXXX. in great We've little that atopic continued data year. as a about we are more call. some VTAMA really those on data well later delivered first commercial clinical sets dermatitis But for We'll III progress not on this as talk that November this
of the some journey both weeks coming sort not, anti-FcRn there's impact in And sets best-in-class no albumin. announced more on healthy that in through far, LDL and shown cohort now. first the the potentially sale cut that so that's And IgG it data or of and least about profile with MAD We IMVT-XXXX with believe at multiple suppression have Graves' antibody at Roche. the and IIb antibody SLE at for all or up of bitoklimab-like still induction us the of from the Phase we dose ascending announced the the the of data of also the phase coming we the data data talk a Immunovant, this little cohort year, a we and maintenance to anti-TLXA SAD in ago in and planned We a a phase. colitis, volunteers, RVT-XXXX, up believe program the showed ulcerative September Obviously, delivered in couple year final our this to more data the June rest beginning of for [indiscernible] XXX-milligram Immunovant of year. study including until the extraordinary in that clinical culmination
are year just gone clinical of be it. so Roivant's chock-full and far. more it teams how So on End of has the could data, proud I a delivering of not really
So here the on our of here to for I talk we've the next which antibody milestone. that slide, acquisition sale that previously the a anti-TLXA about upfront just with us that plan to is messaged, is already for bit billion want million ago, sell [indiscernible] discussed Roche a $X.X to little Telavant, weeks program couple the was a
As a of business. that about XX% owns reminder, [indiscernible]
million that proceeds the close about expect will as that $X.X well next from the be we year. -- well this from So or on $XXX including of transaction, follow-on our milestone as billion close proceeds forma the cash transaction as for as At that pro offering.
equivalents We expect capital billion, Roivant position. $X is for cash extraordinary consolidated of cash which and an
with more this outside on commercial program. Roche the to will Pfizer more and to Japan, bit program about plan what and that partner a we'll the and capital. little with the future of a in And keep do rights the continue on lot call We talk to U.S. will we
on of little As [indiscernible] X. reminder slide a
First maximize across Roche we but of all, will developing Obviously, would work we the adds expertise certainly Roche done to the proud the pharma do had things. a for great have global we program, access continue that and excited been program, think large resources for of continue the company indications. and patients of to were to
to just a Immunovant going transformational people, a it call, and the were as had is people a proper pipeline a investors, this previous remind the of is with of large we've -- number looking opportunity already and to what us. do I on value be of for lot thoughtful. I'll capital, tremendous anything included. said lot opportunity and ever in this patient amount We a phenomenal sense some the capital of generation others. know far capital opportunities as of and we're program going we've have as near -- put FcRn modest before are with there. to and we so I work see exciting transaction a near-term relatively are relative heard And TLXA from We're program. efficiency for capital with that in our to invested the that us, We to the excited that value For to a done we the term large and between
to expect that development rule deals efficient relatively done while smaller continue in And it to beyond return with significant likely look above capital taking think before of that, to transactions. whole we're stock We is opportunity. And those shareholders. a potential more great the side, ones out, But and have never we'll continue anything I we've capital to that be the and upfront components. there's the again, the business I like given opportunity we sum. the to
in over time. about more future X and those things the talk near of all we'll So
As the now it the And frequently a is happened. road the what this of from Slide did does questions answer look data like X, in reminder, my of And the on is, catalyst fact, same has that it deal before. would map that one just well, be year. as in TLXA looks I've end the the gotten at program much investors Crohn's
You near-term catalyst. any didn't have
pipeline tremendously today. Our rich is
from we continuing VTAMA, months in program the the anti-FcRn to obviously, data commercial franchise generate clinical a and data forward coming to in come. programs to months, a XX brepocitinib With with in those at and look especially significant next of both important our other and amount
some So Immunovant a other where of I'm to going programs. do with brief of the review we that, and are at
deeper generated lot the franchise [indiscernible] on have a but data with better that we believe of of We continuing IgG great capable start to have deeper Slide just available coming reminder, than data to anti-FcRn [indiscernible] generate XX as else. hypothesis. And proud behind one on of are to and a in we we indications mid-stage without we an I'll that out able to very prove looking we've where expressing programs, IgG tell we're And going the have. which is same impact X close best it the etokimab, we albumin. And now that clinical both one can are data like LDL a of we from them in delivers matter that think suppression, other anybody be
a programs. really a franchise these of exciting opportunity So for
to and that reminder, cohort, that which, XXXX both ascending XX, fully had innings dose XXX multiple XXX that cohort this dose dose to it multiple way XXX milligrams and IV XXX cohorts the that is to the XXX-milligram from they then expect program. on no all ascending this single single in of designed [indiscernible] all it is this and and As late at dose other volunteer the profile up track. on multiple-ascending single And healthy subcu. point, we've a a at subcutaneous was subcu were higher reveal of dose had reminder, ascending X,XXX IV, as that cohorts month, sending multiple study Slide ascending and XXX clinical signals, delivered milligrams than
beyond, reminder, the ascending IgG of to etokimab amount and was with concerned what far data suppression the XXX-XXXX [indiscernible] of dose a shared all XX, data, on very which, share I picture IgG painted a XXX just suppressing a like we shows to as proceeding Slides that of as etokimab September drug similar Obviously, going XXX. On consistent multiple we were have very in similar we believe not I'm XX do. and much Slide milligrams here. could for everything fully this by XXXX as
down on can baseline up is then the time slightly Albumin this can really on the that's impact at dose-dependent There winding in which data below really and at course course no is time course about. note XX, dose a [indiscernible] showed time again, clear see of Unlike that was dependent Slide data, slightly with on the direction study you on above end albumin batoclimab, in up to placebo, LDL baseline. concerned And sending then etokimab, see LDL no slightly LDL don't multiple And but in unfortunately you impact have the you case, above we see which same albumin. impact remember can achieved. all. be the
or as was this and all with that we XXX-milligram expected once believe met looking So it we to variability minus we across consistency these profile, a said there data sharing LDL in to plus have data tune. always the of variability the forward we the have of we But it. a suggests we're in XX% reminder, strong
potential Graves really matters significantly commercial underappreciated clinically patients point, this think help. can in FCR that a And it validation clinical of indications is for indication target full well. this just as as broad is an year. later a September a J&J Slide with at the new our diseases multiple on including number that in data, own we continue final an shared on the Graves' data, broad continued XX, developments Even to coming target. since [indiscernible] sort we is when field, studies, note, progress the to make of RA reminder to then incredibly And and data just the great it's number across we've see and I we our active that this of
So that continue that of full evaluate plays A and about very, what's to where there. to really as to rich data very excited year to I forward. are really continue strategic ahead, and options data a come about we and generate set will to that communicate believe present themselves months excited
I'm a up, going the Slide on launch XX. VTAMA next provide So to on starting update brief the
So continues overall continued product. script volume but the launch say, pleased see at like uptake continue from to we reactions I'd pleased the clip, we're It steady of and how is physicians be this and stage, from reaction with would -- this fast not as a overall, to quite going. we as patients, grow probably with we at the continues
next to population. to going we launch in psoriasis. in bend larger have volume history. the atopic we're dermatitis be the able with topical for and that excited hopeful the the a best in continue launching curve year, remains more second in particular, and to we're And we're we're This where patient of generate data terrific half So significantly
yield On financials GTN got continue the the XX.X%. process $XX.X We're up sort Slide I'd Revenues did XX, at to build. for say, here. We accreted, contracting through modestly million about we this point. of just the to quarter.
the XX% over build steady So about, state, the I as we would to expect clip get steady we'll think modestly up approach we've that long time communicated. to a some we we've term, at which talked as to time we'll take to and GTN improve there will continue
about including actually permitted. a Slide the across in et else -- has things been And just psoriasis in There's of inecrigenous psoriasis. that month you or are inside especially fold, phenomenal data perspective. as two where the about additional elbow skin aggressively most We is where at one published couple notes we least in the the other good the as the the generated X pernicious were our last we psoriasis of from of comparison efficacy think Finally, inside some is and our are This program have of cetera, our view steroids some in growing, this on psoriasis. XX, talked in can potent competitors not a here. data really and where endocrigenis data see is anybody
So very about psoriasis. in [indiscernible] feel deliver we good what we
out put area, additional in important the some also data, is We onset which the speed which atopic super is itch. for of hepatitis
XX, as just as see in a separation early meaningful we separation hours. As hours had within XX X specifically on Slide a on significant and placebo you clear can XX reduction week visible really and itch within a
feel patients. speed something of onset to a a the lot that matters we very [indiscernible] good that's So about quite and
some phenomenal when XX, endpoint excited And launch. Slide any. this across more we mechanism, there profile X just as So but in this with we data to agent the been as it's of filing data shown profile is that's that you we good we as we're look put is couldn't some get best reminder, just out excited really a clinical safety with as to data ever for to NDA on that published about eventual continue AD across take before, XX, mechanisms, closer be and then to the continue of
In fact, some from the systemic of that looks numerically an efficacy differentiated therapies. profile even
that. and expect reminder, as of Progression forward next really to launch go S&D next So in year expect looking sort early that exciting later to the and year. a
a just upcoming in want Finally, give reminder the data program on side, the brepocitinib. of I to
exciting In some in of say, me. I'd the drug shadow sitting TLXA have really But effective to programs. agent. and ways So of a FcRn sort incredibly brepocitinib been is an the it's
rate best of been about the now shown We that's talked have we on remission the or call. TYKX example, have classes, some last the with numerical for disease, think across II X Crohn's positive best single we Phase studies I the data in that JAK
just agent inflammatory for gun very So a a big potent kind disease. of
excited really which we sort was pivotals here, IIb we about this the are We registrational for which SLE that Phase running for of included are what quarter. would near importantly, we're also dermatomyositis, be study more X program, up term, which in have but plans the reading main X program out the that the our set study of
recently. program. at the of it We've talked in to of the a least and in as that's Hidradenitis of [indiscernible] a will forward study and to it. sort year of challenges that's But big first as so some works the opportunity main run the if sole about generates obviously lot set, of benefit Suppurativa, potential the out that, not in attention proof to focus SLE tracked or the we're is reading And lot setting what if data the be should a we we beyond including have patients, capable we an can think a think to that have as really need concept guess the that's equivalent area run we've an if of an beat quarter for indication next possibility There's agent, in well of it looking order is in highly I we [indiscernible] set that which effective -- we therapies. it ourselves, another
So for brepocitinib. really excited
of data On which Slide study in just looking a next we're out and the beginning seeing reading it of of we of at of year, forward XX XX, with reminder the the study and SLE to NIU have both each the the in -- world. really that design sharing
is wrap I a So relatively quick will up update. here
the which all to on very cash a billion reminder deal, lots this of on closing and phase relatively of that XX. next effect us balance put to quarter great straightforward for financials the the again numbers do won't Slide in here, of would read strong of a giving things consolidated position life. Just of $X I excited but the in our
say top be full excited going the through again say, was road It huge go but than us. year won't hard on that's I Other lot definitely a that, will Roivant, for quarter everybody will hand and to you of I to this help will investors, Slide With way to Q&A. quite And and for possible to the So team to back XXXX, year date. to over our Thank thank everybody. for we you data who to to catalyst I this to the try at it our to help entire XXXX are coming us. map in a make operator we're it XX.
